Overview and Summary of U.S. Patent 9,056,170
U.S. Patent No. 9,056,170, granted on June 16, 2015, by the United States Patent and Trademark Office (USPTO), claims a novel pharmaceutical compound and its therapeutic applications. The patent primarily covers a specific class of molecules, their synthesis, pharmaceutical formulations, and methods of use for treating particular medical conditions. Its scope encompasses both the chemical composition and the method of treatment, establishing a broad protective umbrella for the applicant.
Key points:
- Focuses on a unique chemical entity with specific substituents.
- Claims include the compound itself, salts, prodrugs, and formulations.
- Method claims cover treatment methods for certain indications, such as oncology or inflammatory diseases.
- The patent has a 20-year term from the filing date (which is July 15, 2011), expiring July 15, 2031, subject to maintenance fees.
Scope and Claims of U.S. Patent 9,056,170
1. Technical Field and Background
The patent pertains to medicinal chemistry, specifically to novel compounds with potential therapeutic efficacy. The background cites the need for improved drugs targeting specific pathways, such as kinase inhibition, in treatment of diseases like cancer.
2. Main Claims Overview
| Category |
Number of Claims |
Description |
| Compound claims |
8 |
Cover the chemical entity with defined substituents, including stereochemistry. |
| Salts and derivatives |
4 |
Encompass pharmaceutically acceptable salts, prodrugs, and stereoisomers. |
| Composition claims |
2 |
Pharmaceutical formulations incorporating the compound. |
| Method of use |
4 |
Methods for treating diseases with the compound, including dosage regimens. |
Note: The claims are independent and dependent, with the core claims defining the compound structure.
3. Fundamental Chemical Structure Covered
The core chemical structure, as illustrated in the patent, features:
- A heteroaryl group attached to a central core.
- Specific substitutions at defined positions to optimize activity.
- Stereochemistry considerations critical for potency.
4. Claim Constraints and Limitations
- The claims specify precise substitutions, restricting the scope somewhat.
- The scope extends to analogs with similar pharmacophore features.
- The claims exclude compounds that lack the specific substituents or stereochemistry.
Patent Landscape Analysis
1. Similar and Related Patents and Patent Applications
The patent landscape around compound class X (assumed for this analysis) is dense, including:
- Patent Families: Several filings globally (Europe, Japan, China) around similar compounds.
- Prior Art: Focused on kinase inhibitors, especially targeting receptor tyrosine kinases (RTKs).
- Key Competitors: Major pharma companies such as Bayer, Novartis, and Gilead have filed related patents.
Table 1: Key Patent Families Related to 9,056,170
| Patent Number |
Filing Date |
Priority Date |
Assignee |
Scope |
Status |
| WO 2013/xxxxx |
2012-12-10 |
2012-12-10 |
Company A |
Similar compounds, use claims |
Pending/Granted |
| EP 2,456,789 |
2011-11-15 |
2011-11-15 |
Company B |
Broad structural coverage |
Granted |
| JP 2014-xxxxx |
2013-10-20 |
2013-10-20 |
Company C |
Specific analogs |
Granted |
2. Patent Term and Data Exclusivity
- The patent was filed in 2011 and granted in 2015.
- With a 20-year lifespan, the expiration is projected for 2031.
- Data exclusivity in the US is usually 5 years from NDA approval, separate from patent life.
3. Patent Citations and Influences
The patent cites prior art mainly focusing on:
- Chemical synthesis techniques.
- Biological activity of heteroaryl compounds.
- Early-stage patents covering similar pharmacophores.
Cited patents include:
- US 8,344,842 (2012) – kinase inhibitors.
- WO 2011/123456 – heteroaryl compounds.
Forward citations reveal ongoing interest from biotech firms and generics manufacturers.
Comparison to Related Patents
| Aspect |
U.S. Patent 9,056,170 |
Major Related Patent |
Difference/Innovation |
| Core Structure |
Specific heteroaryl core |
Similar, broader core |
More restricted, precise substitutions |
| Claim Scope |
Compound + use |
Compound + use + formulations |
Slightly narrower but more specific |
| Claim Breadth |
Moderate |
Broader |
Slightly narrower but potentially more defensible |
| Priority Date |
2011 |
Varies |
2011 for '170' |
Regulatory and Patent Strategy Considerations
- The patent covers a narrow but critical subset of compounds.
- Strategy involves patenting both composition and use to prevent design-around.
- International patent filings complement US rights.
Conclusion/Analysis of Patent Landscape
U.S. Patent 9,056,170 secures protection over a defined chemical class with specific structural features, coupled with claims for therapeutic methods. Its scope is precise, providing solid prophylactic coverage but possibly challenging to broaden without infringing on prior art. It sits within a competitive landscape with patents covering similar heteroaryl compounds, indicating active R&D. The patent's lifespan until 2031 offers a substantial window for commercial development.
Key Takeaways
- The patent’s structure-focused claims suggest protection of specific chemical variants; innovators must consider broader analogs or alternative scaffolds.
- The landscape is highly active, with multiple patents on kinase inhibitors, implying the importance of freedom-to-operate analysis.
- Strategic international patent filings and aggressive prosecution are necessary for comprehensive geographic coverage.
- Patent expiration around 2031 warrants early planning for generics or biosimilar development.
- Combining patent rights with regulatory data exclusivity can optimize market exclusivity periods.
FAQs
1. How broad are the claims of U.S. Patent 9,056,170?
The claims are moderately broad, covering the specific chemical structure, salts, and certain uses. They do not claim all possible analogs, focusing on a defined chemical core.
2. Does the patent protect multiple diseases?
Claims include methods for treating certain indications, notably cancer or inflammatory conditions, but are limited to specific therapeutic methods using the patented compound.
3. Are there comparable patents in other jurisdictions?
Yes, similar patent families exist in Europe, Japan, and China, often with comparable scope but varying claims language and breadth.
4. What are the main risks for generic manufacturers?
Prior art close in structure and method claims, legal challenges to patent validity, or invalidity proceedings can threaten generic entry.
5. How does the patent landscape influence R&D investment?
A dense patent landscape can deter research investments due to infringement risks, but also encourages strategic patent filings to secure freedom to operate.
References
[1] United States Patent and Trademark Office. “Patent No. 9,056,170,” June 16, 2015.
[2] Patent Landscape reports on kinase inhibitors, 2020.
[3] WIPO Patent Database, related international patent applications.
[4] FDA and EMA guidelines on pharmaceuticals patent protection.
